| Literature DB >> 27500725 |
Jing He1, Xia Zhang1, Yunbo Wei2, Xiaolin Sun1, Yaping Chen3, Jun Deng4, Yuebo Jin1, Yuzhou Gan1, Xin Hu3, Rulin Jia1, Chuanhui Xu1, Zhaohua Hou2, Yew Ann Leong3, Lei Zhu1, Jinhong Feng2, Yuan An1, Yuan Jia1, Chun Li1, Xu Liu1, Hua Ye1, Limin Ren1, Ru Li1, Haihong Yao1, Yuhui Li1, Shi Chen1, Xuewu Zhang1, Yin Su1, Jianping Guo1, Nan Shen4, Eric F Morand5, Di Yu2,3,4,5, Zhanguo Li1.
Abstract
Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4(+) T cells. The homeostasis of CD4(+) T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27500725 DOI： 10.1038/nm.4148
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440